TORONTO, March 26 /CNW/ - Spectral today announces the presentation of
positive data concerning the use of the Endotoxin Activity Assay (EAA(TM)) at
the 27th Annual International Symposium of Critical Care and Emergency
Medicine, March 27-30, Brussels, Belgium.
Dr John Marshall, Professor of Medicine, and current president of the
International Sepsis Forum will present a plenary lecture entitled
"Endotoxemia in the Critically Ill".
"Spectral's EAA(TM) assay, the only world-wide regulatory approved assay
for endotoxin in the blood stream, continues to gain acceptance from the
presentation of the results of our multiple clinical studies, performed by
leading critical care doctors," stated Dr. Paul Walker, President and CEO.
"Increased levels of endotoxin seem to play a significant role in a number of
different disease processes," continued Dr. Walker.
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Current products include Spectral's FDA approved rapid diagnostic for West
Nile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis
(EAA(TM)) as well as a range of other biological reagents. Spectral's common
shares are listed on The Toronto Stock Exchange under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.
For further information:
For further information: At: Spectral Diagnostics Inc., Dr. Paul Walker,
Chief Executive Officer, (416) 626-3233